Navigation Links
MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs
Date:1/13/2009

f Automated Dosing Reminders on Medication Adherence using HealthVault" Trial

This clinical trial will be completed in 14 months and in three phases: software development, a clinical research study, and subsequent data analysis. 500 subjects will be recruited in the U.S. for the two-part study, which includes a cohort study to assess baseline adherence with glaucoma medications followed by a randomized, controlled trial of the adherence intervention. Approximately 100 subjects will be randomized to participate in the technology-based adherence intervention program. The results of the study will be presented in a peer-reviewed forum upon completion of the trial, which is expected to conclude in mid-2010.

About Glaucoma and Adherence

Glaucoma is the second leading cause of blindness and visual disability worldwide. It's estimated that 2.5 million people in the U.S. are affected by glaucoma, with another 10 million undiagnosed. By the year 2010, worldwide, the number is predicted to be 60 million. Currently, there is no cure for glaucoma. However, studies have shown that reducing the eye pressure with topical medical therapy, office laser or surgery can prevent occurrence or slow disease progression. The majority of patients diagnosed with glaucoma or ocular hypertension are managed initially with medications. However, despite the availability of effective topical therapies, non-adherence in patients with glaucoma is poor and has been reported between 37-59%.

About MEMOTEXT

MEMOTEXT is a specialized healthcare application service provider focused on providing medication adherence intervention solutions. With over 25 years of expertise in patient-stakeholder issues and the telecommunications industry, MEMOTEXT integrates behavior modification, patient education and live support into the everyday lives of patients. MEMOTEXT uses proven methodologies and customized solutions that
'/>"/>

SOURCE MEMOTEXT Personalized Adherence Solutions
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Pennsylvania Patient Safety Authority Launches New Website and Design With New Tagline Analyzing, Educating and Collaborating for Patient Safety
2. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
3. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
4. Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
5. YMCA of the USA Expands Healthy Communities Initiatives With $6.8 Million Grant from the Robert Wood Johnson Foundation
6. Johnson Matthey Medical Announces Expansion
7. Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions
8. Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity
9. Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day
10. Johns Hopkins and Makerere University to collaborate on African health education initiative
11. Johnson & Johnson Begins Tender Offer to Acquire Omrix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... who was diagnosed with Ebola while working for NBC News ... can leave the special isolation unit at Nebraska Medical Center in ... the hospital said Tuesday. A blood test confirmed by the ... 33, can head home to Providence, R.I., NBC News ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute ... to repair a damaged mitral valve as the heart ... developed by Abbott Vascular , is designed to ... condition in which the heart’s mitral valve leaflets fail ... the heart’s left ventricle into the left atrium. The ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... through an animal study that Aspartame can cause lymphoma, ... five 20-ounce bottles of diet soda sweetened with aspartame ... ,The study would be published in March issue ... journal., ,The method and sample adopted were feeding ...
... short breaks can go a long way in making ... study conducted by Massachusetts Institute researchers. // ... Massachusetts Institute of Technology in Cambridge, found that rats' ... pause briefly to rest., ,They suggest that eliminating ...
... cell research in the state with the approval of 61% ... have impeded the initiative. // ,The officials now ... will be initiated. Zach Hall, president of the California Institute ... would commence the project as soon as possible. ...
... Howard has allocated $1.1 billion in health reforms. But his ... ,Mr. Howard said that there was more mental illness previously ... thing is to move on with one’s life. ... ill-informed. ,Though he said that in reality mental ...
... Honolulu: The Hawaii State Hospital has gone down the ranks ... crowding, a status report has revealed//. The status report quotes, ... to meet the June 30th deadline, required to bring the ... had received a one-year extended timeframe till June 30 to ...
... the help of prisoners from Beur jail in Patna to ... near the jail and begged for money to fulfill the ... was kidnapped in Phulwarisharief while he was on his way ... to use their contacts outside the jail to help trace ...
Cached Medicine News:Health News:Task Learning Made Simple By Taking Short Breaks 2Health News:Momentum of Stem cell research impeded by legal challenges 2
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 /PRNewswire/ ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting ... Under the terms of the collaboration, Foundation ... laboratory component of Foundation Medicine,s FoundationOne® assay at the ...
(Date:10/20/2014)... 2014  Luoxis Diagnostics, Inc., a subsidiary of ... that its academic collaborators will present several peer-reviewed ... its novel RedoxSYS Diagnostic System, a first-in-class platform ... in response to injury or illness.  A poster ... clinical marker will be presented by Christopher ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... the risk of cardiovascular hospitalization or death by 24 ... Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and ... that the ATHENA trial was published in the New ... (dronedarone), in addition to standard therapy, significantly reduced the ...
... a study published in The American Journal of ... Clinic psychiatrist Mark Frye, M.D., attempted to identify what ... to experience treatment-emergent mania (TEM).Bipolar disorder, also known as ... mood instability that can be serious and disabling. The ...
Cached Medicine Technology:New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 2New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 3New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 4New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 5New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 6Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder 2Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder 3
Flagship Transcranial Doppler system with multiple channel options, multi-depth options....
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
... have very fine tips and are intended for ... is required. The curved ones are ideal for ... shards. The student versions are for beginners. These ... static free. The Swiss forceps are made from ...
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
Medicine Products: